VS035

About RDR Pharma AG

RD Pharma (RDP) is a privately held biotech, dedicated to the vision that their products will deliver valuable medicines to patients in need.

RDP's leadership team and board of directors are focused on getting their products into clinical trials and addressing the unmet medical needs of patients. The team is comprised of entrepreneurs, drug development experts, and biotech veterans. Their extensive experience ensures that the right questions are asked, the right experiments conducted, and the right clinical studies implemented.

About RDP HPV E7 Oncoprotein VS035

RDP has identified a first-in-class, orally available, small molecule-based new chemical entity (NCE) which induces the proteolysis of the human papilloma virus (HPV)-associated E7 oncoprotein. The lead compound VS035 was selected from more than 64 million compounds employing computer cavity docking simulations (in silico screens). Following selection, 1,000 molecules were chemically synthesized and tested using a proprietary E7 assay. Single agent efficacy of VS035 and OC246 (the back-up compound) has been demonstrated in an HPV-dependent cervix cancer xenograft model. Both compounds reveal clear single agent inhibition of E7 activity. Toxicity in mice was not observed so far. VS035 decomposes E7, thereby stopping uncontrolled cell division, ceasing tumour-induced cell signalling and re-activating the adaptive (and also innate) immune response.

It is anticipated that HPV-induced malignancies, such as cervical, vulvar or anal intraepithelial neoplasia could be treated with VS035 monotherapy. Invasive disease might benefit from combination therapies of VS035 and PD1 inhibitors leading to a potential cure for HPV-induced cancer.

Partnering with RDP

We are seeking partners / investors to support the development of RDP HPV E7 Oncoprotein VS035.

Interested parties should contact Michael Ahrweiler:

Michael.ahrweiler@rdp-pharma.com

Screening process for VS035



Specifications for Inhibitor Selection:

- Clear activity in HPV-induced xenograft model
- Oral availability and favorable pharmacokinetics
- Ability to decompose E7 within its *in vivo* half-life
- Low toxicity
- Compliance with the “Lipinski rule of 5” (drug-ability)
- Ease of synthesis and favorable upscaling properties
- Good patentability (new composition of matter patent and beyond)

Experiments demonstrating the decomposition of E7. The read-out for the screen was the degradation of E7 (primary screen: flow cytometry (cycloheximide [CHX] was the positive control; a shift to the left indicates degradation of E7 -- secondary screen: E7 protein steady state levels under treatment.